RadNet
NASDAQ: RDNT
$63.29 ▼ -2.31  (-3.52%)
At close: Jul 13, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap5.06 Bn
P/E229.12
P/S2.36
Div. Yield0.00
ROIC (Qtr)0.00
Total Debt (Qtr)1.06 Bn
Revenue Growth (1y) (Qtr)22.11
Add ratio to table…

About

RadNet Inc is a leading national provider of diagnostic imaging services in the United States operating 418 imaging centers across nine states as of December 31 2025. The company was founded in 1985 and has grown through a combination of internal development and strategic acquisitions. Its core business consists of delivering outpatient imaging exams that help physicians detect diagnose and monitor a wide range of medical conditions. The centers offer a full suite of…

Read more ↓
Sector: Healthcare Industry: Diagnostics & Research CIK: 0000790526

Investment Thesis

▲ Bull case
  • RadNet's strategic integration of DeepHealth's enterprise AI platform is poised to unlock significant margin expansion and operational leverage beyond current guidance, as evidenced by the company's internal deployments showing tangible efficiency gains like a 33% reduction in ultrasound slot times from 30 to 20 minutes and TechLife reducing exam room closure hours. This productivity enhancement allows RadNet to serve more patients without increasing physical footprint or labor costs, directly improving throughput and revenue per center while mitigating industry-wide technologist shortages. The full rollout of ReportingPro and AI Orchestrator across RadNet's 440-center network will amplify these benefits, converting AI investments into measurable free cash flow growth as deployment capabilities scale, which management acknowledged as a deliberate focus area currently being built to swiftly implement won deals.
  • The company's aggressive push into health system joint ventures, exemplified by the Trinity Health St. Alphonsus partnership yielding $30 million in annual revenues from just five centers, represents a scalable, high-margin growth avenue that is underappreciated by the market. With 155 of 440 centers already in health system partnerships (35.2%) and a robust pipeline of additional opportunities, RadNet is positioning itself as the preferred operating partner for systems seeking cost-effective outpatient imaging solutions. This model leverages RadNet's AI-powered workflow to deliver seamless inpatient-outpatient integration, a capability health systems cannot optimally achieve internally, creating a structural advantage that drives long-term, sticky revenue streams with lower customer acquisition costs and higher retention versus standalone center growth.
  • Radian's Digital Health segment is transitioning into a global technology leader with external revenue reaching 64% of total Digital Health revenue in Q1 2026, up from 51% year-over-year, served by an installed base near 3,000 global customers. This shift, combined with a commercial funnel exceeding $150 million in total contract value and $7 million in signed ARR awaiting go-live, indicates that ARR growth is not only on track to exceed the $140 million year-end target but is likely to accelerate into 2027 with momentum building across Diagnostic Suite, Enterprise Operations, and clinical AI. The 95% year-over-year ARR growth to $97 million, coupled with regulatory approval velocity increasing over 70% year-over-year (26 FDA clearances and 22 CE marks currently, with 12 FDA and 15 CE marks expected), signals a self-reinforcing cycle where commercial success fuels further innovation and market expansion, directly supporting the reaffirmed guidance of $135-$145 million in revenue and $10-$12 million in adjusted EBITDA for Digital Health in 2026 with clear upside beyond.
▼ Bear case
  • RadNet's reliance on advanced imaging growth to drive profitability masks a concerning trend where routine imaging volumes, representing 71% of procedure volume, are nearing stagnation, with management acknowledging they will likely grow only in line with population (low single digits). This shift risks creating a revenue concentration vulnerability, as advanced imaging, while driving over 60% of revenue from just 29.3% of procedures, remains highly sensitive to reimbursement policy changes and utilization fluctuations tied to specific clinical indications like prostate cancer PSMA and brain amyloid PET/CT scans. The company's aggressive focus on upgrading equipment for advanced imaging may inadvertently crowd out routine volume growth opportunities, leaving RadNet exposed if payer policies shift to favor preventive or lower-cost imaging modalities, or if reimbursement for high-margin advanced procedures faces downward pressure amid broader healthcare cost containment efforts.
  • Despite strong ARR growth in Digital Health, the segment's current adjusted EBITDA margin is intentionally diluted due to strategic investments in deployment capabilities, commercial teams, and infrastructure, with management confirming Q1 2026 is a trough year for margins as per Investor Day plans. This margin pressure is exacerbated by the dilutive impact of recent acquisitions like Gleamer, iCAD, and C-MODE, which are not yet profitable and require significant integration effort, while the path to the long-term 20%-40% EBITDA margin target depends on uncertain factors such as achieving widespread T-code reimbursement for AI solutions (currently limited to thyroid ultrasound with only 60%-70% payer coverage) and successfully monetizing emerging capabilities like breast ultrasound and neuro MR AI. The market may be overestimating the speed at which these AI tools transition from productivity gains to billable revenue, creating a risk that Digital Health remains a drag on consolidated profitability longer than anticipated if deployment lags or reimbursement adoption slows.
  • RadNet's acquisition-driven growth strategy, while boosting top-line revenue, introduces integration execution risk and financial leverage concerns that are underappreciated given the company's modest but increasing debt profile. The acquisitions of Radiology Regional (13 centers), Northwest Radiology (6 centers), and Gleamer SAS, combined with the Trinity Health joint venture, deployed substantial capital in Q1 2026, increasing net debt to approximately $631 million and maintaining a leverage ratio near 2.0x adjusted EBITDA. Although management emphasizes prudent cash management and expects deleveraging, the success of this strategy hinges on seamless integration of diverse operating systems, cultures, and technologies across geographically dispersed assets—particularly challenging for the international Gleamer integration—and any delays in realizing synergies or achieving projected run rates could pressure free cash flow generation and constrain future M&A capacity, especially if same-center performance fails to consistently offset integration costs.

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 WAT Waters Corp /De/ 31,055.11 Bn69,126.888,236.164.86 Bn
2 TMO Thermo Fisher Scientific Inc. 191.02 Bn27.634.2343.16 Bn
3 DHR Danaher Corp /De/ 137.16 Bn37.325.5418.48 Bn
4 IDXX Idexx Laboratories Inc /De 42.82 Bn39.099.630.83 Bn
5 NTRA Natera, Inc. 39.09 Bn-172.7115.630.02 Bn
6 A Agilent Technologies, Inc. 37.61 Bn26.605.200.30 Bn
7 IQV Iqvia Holdings Inc. 34.23 Bn35.842.0615.83 Bn
8 ILMN Illumina, Inc. 28.14 Bn32.986.401.49 Bn